Gilead completed three major acquisitions in 2026 totaling $14.77 billion:
Arcellx ($7.59B in February), Ouro Medicines ($2.18B in March), and Tubulis (up to $5B announced April 7)123.
CFO Andrew Dickinson stated it's less likely Gilead will pursue more sizable M&A this year, shifting focus to integration, but the door remains open for compelling opportunities2.
CEO Daniel O’Day emphasized the pipeline's strength, high bar for deals, and passing on dozens of non-qualifying opportunities; recent buys build oncology portfolio with ADCs, CAR-T, and more23.
Tubulis deal includes $3.15B upfront and $1.85B milestones, adding next-gen ADC tech (P5, Alco5) and clinical assets TUB-040, TUB-03014.
All deals expected to close in Q2 2026; prior Tubulis/Arcellx partnerships informed acquisitions13.
Sources:
1. https://www.biopharmadive.com/news/gilead-tubulis-acquire-deal-adc-cancer/816823/
2. https://www.biospace.com/business/gilead-less-m-a-happy-now-but-door-still-open-for-compelling-opportunities
3. https://www.fiercebiotech.com/biotech/3-new-acquisitions-digest-gilead-shifts-focus-pipeline-has-never-been-stronger
4. https://www.bioxconomy.com/partnering/gilead-expands-antibody-conjugate-capabilities-with-5bn-tubulis-buy